Alpha Cognition Inc (ACOG) Stock Price, Quote & News

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatit...

Industry: Biotechnology

Sector: Healthcare

Phone: 604-564-9244

Website: www.alphacognition.com

Address:

750 West Pender Street, Suite 1200, Vancouver, Canada

FlowerInTheCellar Oct. 6 at 1:33 PM

$ACOG https://www.businesswire.com/news/home/20251006913298/en/Alpha-Cognition-to-Present-Clinical-Data-at-ASCP-Annual-Meeting

0 · Reply

NetworkNewsWire Oct. 3 at 5:53 PM

BioMedNewsBreaks — $ACOG Prices $35 Million Oversubscribed Public Offering https://ibn.fm/Zsy1b

0 · Reply

d333gs Oct. 2 at 1:59 PM

$ACOG I don't see any trade activity !?

0 · Reply

Bioinvester001 Oct. 2 at 1:38 PM

$ACOG The overhang of a cap raise is now gone, and the company has an extended runway of cash. It looks like accelerated sales on the way.

0 · Reply

Arcides Oct. 1 at 9:58 PM

$ACOG looks like wanna make first bounce from 200dma, very steep though

0 · Reply

jumptime Oct. 1 at 7:52 PM

$ACOG Way better day then I could have imagined.

1 · Reply

DARKP00L Oct. 1 at 4:59 PM

$ACOG 12:58 on Oct. 01 2025 Alpha Cognition shares are trading higher. The company announced the pricing of its $35 million oversubscribed underwritten public offering of 5,600,000 common shares at a public offering price of $6.25 per share. #tradeideas

0 · Reply

Channelchek Oct. 1 at 1:49 PM

We're excited to feature Alpha Cognition ($ACOG) as a participating company at the Noble Capital Markets Emerging Growth Virtual Equity Conference, October 8-9. Don't miss the chance to explore unique investment opportunities. 1x1 Meetings available for qualified investors. 📅 Register: https://www.meetmax.com/sched/event_125441/investor_reg_new.html?attendee_role_id=NOBLE_INVESTOR #NobleConference #EmergingGrowth #InvestorEvent

0 · Reply

GeorgeJonesCountryMusic Oct. 1 at 1:12 PM

$ACOG wow, 8 new watchers since yesterday

0 · Reply

JackCampbell Oct. 1 at 8:22 AM

$ACOG 35M USD offering was oversubscribed, signals that the new investors are very confident in ACOGs execution.

0 · Reply

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Sep 30, 2025, 11:14 PM EDT - 7 days ago

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Sep 30, 2025, 4:58 PM EDT - 7 days ago

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Aug 28, 2025, 1:00 PM EDT - 5 weeks ago

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Aug 15, 2025, 5:10 PM EDT - 7 weeks ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Aug 14, 2025, 7:54 PM EDT - 7 weeks ago

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 8:30 AM EDT - 7 weeks ago

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Jul 29, 2025, 8:30 AM EDT - 2 months ago

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Jul 8, 2025, 8:30 AM EDT - 3 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Jul 1, 2025, 5:05 PM EDT - 3 months ago

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

May 19, 2025, 4:35 PM EDT - 5 months ago

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

May 19, 2025, 10:25 AM EDT - 5 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

May 15, 2025, 9:51 PM EDT - 5 months ago

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:30 AM EDT - 5 months ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 1, 2025, 8:30 AM EDT - 5 months ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Apr 30, 2025, 7:30 AM EDT - 5 months ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 28, 2025, 8:30 AM EDT - 5 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Apr 10, 2025, 8:30 AM EDT - 6 months ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Apr 1, 2025, 4:27 PM EDT - 6 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Mar 31, 2025, 9:50 PM EDT - 6 months ago

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:30 AM EDT - 6 months ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 4:30 PM EDT - 7 months ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 18, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Feb 12, 2025, 8:30 AM EST - 8 months ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Jan 30, 2025, 11:05 AM EST - 8 months ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 14, 2025, 8:30 AM EST - 9 months ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 8, 2025, 8:30 AM EST - 9 months ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Jan 6, 2025, 8:30 AM EST - 9 months ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Dec 16, 2024, 2:56 PM EST - 10 months ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Dec 16, 2024, 11:51 AM EST - 10 months ago

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Dec 12, 2024, 6:41 PM EST - 10 months ago

Alpha Cognition Announces Voluntary Delisting from CSE

Dec 11, 2024, 8:30 AM EST - 10 months ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Nov 15, 2024, 5:00 PM EST - 11 months ago

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Nov 12, 2024, 9:22 AM EST - 11 months ago

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

FlowerInTheCellar Oct. 6 at 1:33 PM

$ACOG https://www.businesswire.com/news/home/20251006913298/en/Alpha-Cognition-to-Present-Clinical-Data-at-ASCP-Annual-Meeting

0 · Reply

NetworkNewsWire Oct. 3 at 5:53 PM

BioMedNewsBreaks — $ACOG Prices $35 Million Oversubscribed Public Offering https://ibn.fm/Zsy1b

0 · Reply

d333gs Oct. 2 at 1:59 PM

$ACOG I don't see any trade activity !?

0 · Reply

Bioinvester001 Oct. 2 at 1:38 PM

$ACOG The overhang of a cap raise is now gone, and the company has an extended runway of cash. It looks like accelerated sales on the way.

0 · Reply

Arcides Oct. 1 at 9:58 PM

$ACOG looks like wanna make first bounce from 200dma, very steep though

0 · Reply

jumptime Oct. 1 at 7:52 PM

$ACOG Way better day then I could have imagined.

1 · Reply

DARKP00L Oct. 1 at 4:59 PM

0 · Reply

Channelchek Oct. 1 at 1:49 PM

0 · Reply

GeorgeJonesCountryMusic Oct. 1 at 1:12 PM

$ACOG wow, 8 new watchers since yesterday

0 · Reply

JackCampbell Oct. 1 at 8:22 AM

$ACOG 35M USD offering was oversubscribed, signals that the new investors are very confident in ACOGs execution.

0 · Reply

Stmkr Oct. 1 at 7:39 AM

$ACOG This will be above $6.25 today. Decent offering. No warrants. Should help commercialization. No cash overhang to profitability

2 · Reply

FlowerInTheCellar Oct. 1 at 3:54 AM

$ACOG https://www.businesswire.com/news/home/20250930007215/en/Alpha-Cognition-Inc.-Announces-Pricing-of-%2435-Million-Oversubscribed-Public-Offering-of-Common-Shares

1 · Reply

Bioinvester001 Sep. 30 at 11:09 PM

$ACOG Shelf offering activated. Looks like it was needed to accelerate marketing, payment system, etc. There's something to this acceleration, as they do have a two year runway for operations. BO plans?

3 · Reply

ucantcatchmegaythots Sep. 30 at 10:11 PM

$ACOG it's not that far off closing price tomorrow, they're doing an offering with no disclosed terms... is this going to tank tomorrow?... what a weird situation

1 · Reply

DonCorleone77 Sep. 30 at 9:10 PM

$ACOG Alpha Cognition announces common stock offering, no amount given

1 · Reply

ForestFoxes Sep. 30 at 3:06 AM

$ACOG image I found in my files dated 2024.09.11 ... I'm surprised about the direction of the s/p 😳 I also noticed we lost one Watcher as the count was 333 ... and it's 332 today 😅

1 · Reply

MTBKNG9 Sep. 29 at 3:23 PM

$ACOG ..never ending dilution....every day

0 · Reply

intratio Sep. 28 at 4:31 PM

Price action $ACOG: bearish capitulation (-4.8%) / severe structural weakness (-10.8%). Theme: Momentum sensitivity high. Multiple negative catalysts creating downward spiral. DOWN / ____.... | ST:[--]vv LT:[--]vvPrice action $ACOG: bearish capitulation (-4.8%) / severe structural weakness (-10.8%). Theme: Momentum sensitivity high. Multiple negative catalysts creating downward spiral. DOWN / ____.... | ST:[--]vv LT:[--]vvPrice action $ACOG: bearish capitulation (-4.8%) / severe structural weakness (-10.8%). Theme: Momentum sensitivity high. Multiple negative catalysts creating downward spiral. DOWN / ____.... | ST:[--]vv LT:[--]vv

0 · Reply

Deltavic Sep. 26 at 8:08 PM

$ACOG IR needs to address this tariff problem ASAP. Silence ain’t golden.

1 · Reply

Team_Zissou Sep. 26 at 8:02 PM

$ACOG I’m happy to report Schwab allowed my electronic purchase of ACOG shares today, no need to call in. I couldn’t resist the price today…

0 · Reply

BottomQuark Sep. 26 at 7:12 PM

$ACOG Reddit post from 7/9/25 that discusses impact of tariffs on ACI: https://www.reddit.com/r/AlphaCognition/comments/1lvj2kc/alpha_cognition_will_largely_avoid_any_trump/

3 · Reply

GeorgeJonesCountryMusic Sep. 26 at 6:53 PM

$ACOG guess Schwab saw something they didn’t like.

0 · Reply

Market Cap	154.68M
Revenue (ttm)	0.00
Net Income (ttm)	-14.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	39,000
Avg Vol	79,884
Day's Range	N/A - N/A
Shares Out	20.90M
Stochastic %K	57%
Beta	2.63
Analysts	Sell
Price Target	$27.50